Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms
- PMID: 16914564
- DOI: 10.1158/1078-0432.CCR-06-0944
Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms
Abstract
Although numerous immunotherapeutic strategies have been studied in patients with cancer, consistent induction of clinical responses remains a formidable challenge. Cancer vaccines are often successful at generating elevated numbers of tumor-specific T lymphocytes in peripheral blood, however, despite this, tumors usually continue to grow unabated. Recent evidence suggests that endogenous regulatory cells, known to play a major role in the induction of immune tolerance to self and prevention of autoimmunity, as well as suppressive myeloid cells invoked in the tumor-bearing state, may be largely responsible for preventing effective antitumor immune responses. This review will focus on the major regulatory cell subtypes, including CD4(+)CD25(+) T-regulatory cells, type 1 regulatory T cells, natural killer T cells, and immature myeloid cells. Studies in humans and in animal models have shown a role for all of these cells in tumor progression, although the mechanisms by which they act to suppress immunity remain largely undefined. Elucidation of the dominant molecular mechanisms mediating immune suppression in vivo will allow more precise targeting of the relevant regulatory cell populations, as well as the development of novel strategies and clinical reagents that will directly block molecules that induce the suppression of antitumor immunity.
Similar articles
-
Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.Clin Cancer Res. 2007 Apr 1;13(7):2100-8. doi: 10.1158/1078-0432.CCR-06-1662. Clin Cancer Res. 2007. PMID: 17404092 Clinical Trial.
-
Tumor-host immune interactions and dendritic cell dysfunction.Adv Cancer Res. 2004;92:13-27. doi: 10.1016/S0065-230X(04)92002-7. Adv Cancer Res. 2004. PMID: 15530555 Review.
-
Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy.Curr Opin Investig Drugs. 2007 Dec;8(12):1002-8. Curr Opin Investig Drugs. 2007. PMID: 18058571 Review.
-
Suppression of anti-cancer immunity by regulatory T cells: back to the future.Semin Cancer Biol. 2006 Apr;16(2):137-49. doi: 10.1016/j.semcancer.2005.11.007. Epub 2006 Jan 11. Semin Cancer Biol. 2006. PMID: 16376101 Review.
-
Host immune responses to cervical cancer.Curr Opin Obstet Gynecol. 2009 Feb;21(1):54-9. doi: 10.1097/GCO.0b013e32831a9890. Curr Opin Obstet Gynecol. 2009. PMID: 19125004 Review.
Cited by
-
Tumor associated regulatory dendritic cells.Semin Cancer Biol. 2012 Aug;22(4):298-306. doi: 10.1016/j.semcancer.2012.02.010. Epub 2012 Mar 6. Semin Cancer Biol. 2012. PMID: 22414911 Free PMC article. Review.
-
The Role of MicroRNAs in Regulatory T Cells and in the Immune Response.Immune Netw. 2011 Feb;11(1):11-41. doi: 10.4110/in.2011.11.1.11. Epub 2011 Feb 28. Immune Netw. 2011. PMID: 21494372 Free PMC article.
-
Forging a link between oncogenic signaling and immunosuppression in melanoma.Oncoimmunology. 2013 Feb 1;2(2):e22745. doi: 10.4161/onci.22745. Oncoimmunology. 2013. PMID: 23525189 Free PMC article.
-
Current approaches in dendritic cell generation and future implications for cancer immunotherapy.Cancer Immunol Immunother. 2007 Oct;56(10):1513-37. doi: 10.1007/s00262-007-0334-z. Epub 2007 May 15. Cancer Immunol Immunother. 2007. PMID: 17503040 Free PMC article. Review.
-
Tumors induce the formation of suppressor endothelial cells in vivo.Cancer Immunol Immunother. 2010 Feb;59(2):267-77. doi: 10.1007/s00262-009-0747-y. Cancer Immunol Immunother. 2010. PMID: 19669642 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials